Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

Core Insights - Nuwellis, Inc. has appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026, enhancing the board's expertise in public company leadership, capital markets, and medical device commercialization [1][2] Group 1: Board Appointments - The appointments are aimed at reinforcing operational discipline and long-term value creation for the company [2] - Martin J. Emerson has extensive experience in leading medical device organizations and has successfully guided companies through strategic transformations and acquisitions [3][4] - David A. McDonald brings over 25 years of experience in healthcare capital markets and corporate development, having raised nearly $200 million in capital during his career [5][6] Group 2: Company Overview - Nuwellis, Inc. focuses on advancing precision fluid management technologies for cardiorenal conditions, developing solutions for patient care through monitoring, therapy, and data-informed clinical decision-making [7] - The company's portfolio includes both commercially available and development-stage technologies aimed at addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [7] Group 3: Product Highlight - The Aquadex SmartFlow system is designed to remove excess fluid from patients suffering from hypervolemia, indicated for both temporary and extended use in adult and pediatric patients [8]